Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.
Louise K MercerJames B GallowayMark LuntRebecca DaviesAudrey Al LowWilliam Gregory DixonKath D WatsonDeborah P M SymmonsKimmie L HyrichPublished in: Annals of the rheumatic diseases (2016)